神经退行症:2024年更新
1Department of Pathology, Nash Family Department of Neuroscience, Department of Artificial Intelligence & Human Health, Neuropathology Brain Bank & Research CoRE, Ronald M. Loeb Center for Alzheimer's Disease, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Free neuropathology
|January 17, 2025
概括
本综述总结了2023年神经退行性疾病中关键的神经病理学研究. 进步包括重复头部冲击的早期变化和人工智能驱动的大脑年龄分析.
科学领域:
- 神经病理学神经病理学
- 神经退行性疾病 神经退行性疾病
- 实验病理学实验病理学
背景情况:
- 神经病理学领域对于理解神经退行性疾病至关重要.
- 基于人体组织的研究对实验和临床神经病理学家至关重要.
- 本系列之前的评论已经为强调有影响力的研究树立了先例.
研究的目的:
- 审查去年关于神经退行性神经病理学的多样化和有影响力的研究.
- 专注于与神经病理学家有关的基于人体组织的研究.
- 为了平衡不同神经退行性疾病类别,方法和方法的选择性研究.
主要方法:
- 使用了古典和最先进的方法.
- 技术包括临床病理解剖学相关研究.
- 先进的方法包括单细胞RNA测序,人工智能和患者衍生的人类诱导的多能干细胞模型.
主要成果:
- 研究表明,在重复头部冲击 (RHI) 的年轻患者中,病理变化最早出现.
- 在莱维体病亚型中阐明了额外金字塔症状的纵向轨迹.
- 在阿尔茨海默病中细胞类型特定的多基因风险被映射到神经病理学.
- 使用人工智能开发了一种使用人工智能测量组织学大脑年龄加速的新方法.
- 分析了25年来脑血管病理的趋势.
- 研究了RHI和TDP-43/海马硬化症之间的关联.
- 研究了神经退行症中的微质/T细胞相互作用.
- 研究了病毒暴露对神经退行性疾病风险的影响.
- 研究了聚聚胺重复扩张障碍.
结论:
- 审查的研究总体显示了神经退行性疾病神经病理学的进展幅度.
- 基于人体组织的研究继续成为我们理解的基石.
- 不同方法的整合,从经典到人工智能驱动的方法,正在加速发现.
相关概念视频
01:37Neural Regulation
39.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.1K
01:15Neurogenesis and Regeneration of Nervous Tissue
703
In the CNS, neurogenesis, the birth of new neurons from stem cells, is limited to the hippocampus in adults. In other regions of the brain and spinal cord, neurogenesis is almost non-existent due to inhibitory influences from neuroglia, especially oligodendrocytes, and the absence of growth-stimulating cues. The myelin produced by oligodendrocytes in the CNS inhibits neuronal regeneration. Furthermore, astrocytes proliferate rapidly after neuronal damage, forming scar tissue that physically...
703
01:15Parkinson's Disease: Overview
456
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
456
01:26Alzheimer's Disease: Overview
439
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
439
01:01Neuroplasticity
281
Neuroplasticity reflects the brain's remarkable capacity to adapt and evolve, responding dynamically to learning, experiences, or injury by reorganizing its neural circuitry. This reorganization involves creating new neural connections and refining old ones through a series of biological processes that contribute to the brain's lifelong development and adaptability.
281
01:22Alzheimer's Disease: Treatment
160
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
160